Baudax Bio (Baudax Bio) FCF Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Baudax Bio's Free Cash Flow for the three months ended in Sep. 2023 was $-2.41 Mil. Baudax Bio's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Baudax Bio's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, Baudax Bio's current FCF Yield % is -3,281.19%.

The historical rank and industry rank for Baudax Bio's FCF Margin % or its related term are showing as below:

BXRXQ' s FCF Margin % Range Over the Past 10 Years
Min: -9066.33 Med: -4580.83 Max: -1127.34
Current: -1127.34

During the past 6 years, the highest FCF Margin % of Baudax Bio was -1127.34%. The lowest was -9066.33%. And the median was -4580.83%.

BXRXQ's FCF Margin % is ranked worse than
76.86% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs BXRXQ: -1127.34

Baudax Bio FCF Margin % Historical Data

The historical data trend for Baudax Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio FCF Margin % Chart

Baudax Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-9,066.33

-4,580.83

-2,191.73

Baudax Bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-	-298.11	-	-	-

Competitive Comparison of Baudax Bio's FCF Margin %

For the Biotechnology subindustry, Baudax Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baudax Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Baudax Bio's FCF Margin % falls into.

Baudax Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Baudax Bio's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-27.813	/	1.269
	=	-2,191.73 %

Baudax Bio's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-2.413	/	0
	=	%

Baudax Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of Baudax Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Baudax Bio (Baudax Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Lapp Road, Malvern, PA, USA, 19355

Website

https://www.baudaxbio.com

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.

Executives

Natalie Mcandrew	officer: Interim CFO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim	director	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore	officer: Corporate Controller/Secretary, other: PFO and PAO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood	director, officer: President and CEO	88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten	officer: Chief Financial Officer	490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake	director, officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc.	10 percent owner	1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341